Scientists Find Master Switch That Stops Melanoma Growth

Scientists just found a single molecule that acts like a double agent in skin cancer, helping tumors grow while simultaneously blocking the immune system from fighting back.

Researchers at NYU Langone Health discovered that a protein called HOXD13 plays a surprising dual role in melanoma. It feeds tumors by building blood vessels that deliver oxygen and nutrients, while also creating a protective shield that keeps cancer-fighting immune cells away.

The team studied tumor samples from over 200 melanoma patients across the United States, Brazil, and Mexico. They found that patients with high HOXD13 levels had fewer cytotoxic T cells, the immune warriors responsible for destroying cancer cells.

When researchers turned off HOXD13 in laboratory experiments, something remarkable happened. Tumors shrank, and T cells could suddenly infiltrate the cancerous tissue they'd been blocked from entering before.

The protein works by activating several biological pathways at once. It triggers the growth of new blood vessels through signals like VEGF, the same pathway many cancer drugs already target. It also raises levels of a substance called adenosine, which acts like a force field around tumors, slowing down and blocking immune cells.

Lead researcher Dr. Pietro Berico explains that HOXD13 is a transcription factor, a type of protein that controls how genetic instructions become the building blocks of our bodies. In melanoma, it essentially rewrites the rules to favor cancer.

The Bright Side

The discovery opens a clear path forward for treatment. Clinical trials are already testing drugs that block VEGF receptors and adenosine receptors in melanoma patients, and some studies are combining these medications with immunotherapy.

The NYU team plans to explore combination treatments specifically for patients with high HOXD13 levels. They're also investigating whether this same protein drives other cancers, including certain brain tumors and bone cancers, where HOXD13 levels are also elevated.

Dr. Eva Hernando-Monge, the study's senior investigator, notes that targeting both the blood supply and the immune barrier at once could hit cancer from two sides simultaneously. Instead of just starving tumors or just boosting immunity, doctors might be able to do both.

The research, published in Cancer Discovery and funded by the National Institutes of Health and multiple cancer foundations, represents years of international collaboration. Confirming HOXD13's role required experiments in mice and human melanoma cell lines, plus blocking the protein at multiple points to prove its importance for tumor survival.

For the 100,000 Americans diagnosed with melanoma each year, this master switch might become a master key to better treatment.